Pharmacyclics has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see the disclaimer for this website.
Pharmacyclics Inc. (Nasdaq: PCYC) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs. Currently, we have three candidates in clinical development and several molecules in preclinical development.
- Ibrutinib (PCI-32765), first-in-human, oral therapy that is a selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor being investigated in B-cell hematologic malignancies.
- PCI-27483, a subcutaneously administered Factor VIIa inhibitor targeting tissue factor expressing tumors in oncology (being investigated in pancreatic cancer).
- Abexinostat hydrochloride (PCI-24781), an oral Histone Deacetylase (HDAC) inhibitor being investigated in oncology applications, such as lymphomas and solid tumor malignancies.
- BTK Inhibitor compounds for autoimmune diseases in preclinical development.
- Isoform selective HDAC8 inhibitors in preclinical development.
Recent Releases
May 10, 2012
Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent Developments
Events
 |
Mar 15, 2012 | Second Quarter Fiscal 2012 Financial Results |
|
Feb 27, 2012 | Citi Global Health Care Conference |
